USES: Bronchicine CAe is licensed for the vaccination of healthy dogs 8 weeks of age or older as an aid in the control of canine infectious tracheobronchitis (kennel cough) caused by Bordetella bronchiseptica. Bronchicine CAe is prepared from antigenic material extracted from the Bordetella bronchiseptica bacterium. An immunogenic strain of B. bronchiseptica is grown to a high yield, then subjected to a proprietary process which extracts the antigens from the B. bronchiseptica cells. The residual cell debris is then removed, resulting in a product which retains the desirable immunologic qualities of a whole cell bacterin, while helping reduce toxic and other undesirable side effects sometimes associated with whole cell bacterins. Bronchicine CAe is a killed cellular extract of the Bordetella bronchiseptica bacterium.
PRECAUTIONS: Store at 35°−45° (2°−7°C). Prolonged exposure to higher temperatures may adversely affect potency. Do not freeze. Use entire contents when first opened. Transient local irritation at the site of injection, though rare, may occur subsequent to use of this product. As with many vaccines, anaphylaxis may occur after use. Initial antidote of epinephrine is recommended and should be followed with appropriate supportive therapy. For Veterinary Use Only. Technical inquiries should be directed to Zoetis Veterinary Services, 1-888-963-8471 (USA).
KEY BENEFITS: • Cellular antigen extract. An additional proprietary step during processing to remove extraneous proteins helps decrease vaccine reactivity. • Non-adjuvanted. • Convenient subcutaneous (SC) parenteral administration. • Supported by our Petcare Immunization Support Guarantee (ISG).
